Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Cost of Revenue (2023 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Cost of Revenue for 3 consecutive years, with $660000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cost of Revenue fell 85.66% year-over-year to $660000.0, compared with a TTM value of -$9.3 million through Sep 2025, down 178.67%, and an annual FY2024 reading of $3.2 million, down 73.74% over the prior year.
  • Cost of Revenue was $660000.0 for Q3 2025 at Fennec Pharmaceuticals, down from $967000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $6.1 million in Q4 2023 and bottomed at -$11.3 million in Q4 2024.
  • Average Cost of Revenue over 3 years is $780363.6, with a median of $660000.0 recorded in 2025.
  • Peak annual rise in Cost of Revenue hit 310.81% in 2024, while the deepest fall reached 286.44% in 2024.
  • Year by year, Cost of Revenue stood at $6.1 million in 2023, then plummeted by 286.44% to -$11.3 million in 2024, then skyrocketed by 105.84% to $660000.0 in 2025.
  • Business Quant data shows Cost of Revenue for FENC at $660000.0 in Q3 2025, $967000.0 in Q2 2025, and $373000.0 in Q1 2025.